Cargando…

Clinical utility of rivaroxaban in stroke prevention associated with nonvalvular atrial fibrillation – patient considerations

The direct factor Xa inhibitor rivaroxaban was the first within the group of orally available direct factor Xa inhibitors to gain clinical approval for oral anticoagulation in patients with nonvalvular atrial fibrillation in 2011. The –xabans, as drugs from the group of oral direct factor Xa inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahrens, Ingo, Bode, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3938442/
https://www.ncbi.nlm.nih.gov/pubmed/24591854
http://dx.doi.org/10.2147/JBM.S32957